Vaccitech plc Acquires Avidea Technologies to Expand SNAPvax Pipeline

Sanofi to Acquire Vicebio for Up to $1.6 Billion

July 25, 2025

Biotechnology

Sanofi will acquire clinical-stage biopharmaceutical company Vicebio in a deal worth up to $1.6 billion, including $1.15 billion upfront and $450 million in milestone payments. Vicebio, created by Medicxi using the University of Queensland's Molecular Clamp technology, develops multivalent vaccines targeting respiratory viruses and recently advanced a bivalent RSV/hMPV candidate into Phase 1 trials.

AstraZeneca Acquires Icosavax

December 12, 2023

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Icosavax, a Seattle-based clinical-stage biopharmaceutical company, in a cash tender offer valuing the deal at approximately $0.8bn upfront and up to $1.1bn including contingent payments. The acquisition brings Icosavax's virus‑like particle (VLP) platform and Phase III‑ready combination RSV/hMPV vaccine candidate IVX‑A12 into AstraZeneca's Vaccines & Immune Therapies late‑stage pipeline to strengthen respiratory vaccine capabilities for older adults and vulnerable populations.

GSK Acquires Affinivax, Inc.

August 16, 2022

Biotechnology

GSK plc acquired clinical-stage biopharmaceutical company Affinivax, Inc., paying $2.1 billion upfront and up to $1.2 billion in potential development milestones to gain the MAPS vaccine platform and a 24‑valent pneumococcal vaccine candidate (AFX3772) in development. The acquisition (100% of outstanding shares) expands GSK's vaccines R&D capabilities and pipeline, with AFX3772 in phase II and preparations underway for phase III.

Agilent Technologies Acquires Avida Biomed

January 4, 2023

Biotechnology

Agilent Technologies has acquired Avida Biomed, an early-stage developer of high-performance NGS target enrichment workflows for cancer research. The acquisition augments Agilent's SureSelect portfolio and expands its capabilities into high-growth clinical research and diagnostics markets by adding Avida's chemistries and automatable assays compatible with Agilent platforms.

Avant Technologies Proposes Acquisition of Ainnova Tech to Consolidate Vision AI JV

May 13, 2025

Healthcare Services

Avant Technologies has entered formal negotiations to acquire its joint-venture partner Ainnova Tech (operating through Ai-nova Acquisition Corp.), aiming to merge the businesses ahead of an FDA pre-submission meeting. The deal is intended to streamline regulatory coordination, speed clinical development and support U.S. market entry for the Vision AI clinical screening platform currently piloted across Latin America.

InductiveHealth Acquires Envision Technology Partners

January 29, 2025

Software

InductiveHealth has acquired Envision Technology Partners to combine disease and syndromic surveillance capabilities with Envision’s immunization information system (WebIZ), creating a unified public health platform. The deal aims to improve interoperability across public health systems, accelerate implementations, and enhance analytics for federal, state and local public health agencies.